CALGARY, May 14, 2020 /CNW/ - Nanalysis Scientific
Corp. ("Nanalysis" or "the Company", TSXV: NSCI, OTCQX: NSCIF,
FRA: 1N1) announces today that Mr. Steve Meszaros has resigned from the company's
board of directors for personal reasons, effective May 13, 2020.
"On behalf of the Board of Directors, I would like to thank Mr.
Meszaros for his time and dedication to Nanalysis over the past 6
years. Steve has been instrumental in helping build the company
thus far." stated Martin Burian,
Chairman, Nanalysis.
Sean Krakiwksy, CEO of Nanalysis states "We have been very
fortunate to have Steve as an active shareholder and Director over
the past 6 years, as we achieved critical milestones in our
evolution as a company. His business instincts are second-to-none,
which I experienced regularly as he mentored me as CEO, and his
precious capital was the lifeblood of the company for many years
before going public. We will all miss his formal association with
Nanalysis but will continue to maintain and strengthen our
relationship with him as an informal supporter."
Replacing Mr. Meszaros is Mr. Guido
Cloetens. Mr. Cloetens joins the Board of Directors
effective May 13, 2020. Mr. Cloetens
brings over 30 years of capital market experience. He is the
current Chief Executive Officer and Chairman of Elysee Developments
Corp. and serves as a director at Edgemont Gold Corp. Guido was
instrumental in facilitating the RTO of Canvass Ventures by
Nanalysis in June 2019, and has
assisted Nanalysis in raising capital and has been providing
advisory services associated with the Company's acquisition
strategy. His business acumen and expertise are welcome additions
to the Company.
About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX:
NSCIF, FRA: 1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV) in
Canada with ticker symbol 'NSCI'
and over the counter in the United
States under the ticker symbol 'NSCIF'. The company's
business is what we term "MRI for industry": It develops and
manufactures portable Nuclear Magnetic Resonance (NMR)
spectrometers or analyzers for laboratory and industrial markets.
The NMReady60™ was the first fully featured portable NMR
spectrometer in a single compact enclosure requiring no liquid
helium or any other cryogens, and the company has followed-up that
initial offering with new products and continues to have a strong
innovation pipeline. Nanalysis recently announced that it intends
to begin selling a 100MHz device in mid-2020. The Company's new
device will be the most powerful non-cryogen, permanent magnet NMR
device ever brought to market.
Nanalysis devices are used by chemical professionals in many
industries (oil and gas, chemical, mining, pharma, biotech, flavor
and fragrances, agrochemicals, and more) as well as numerous
government and university research labs around the world. The
company continues to exploit new global market opportunities
independently and with partners.
Notice regarding Forward Looking Statements and Legal
Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Nanalysis Scientific Corp.